ICRF has awarded more than $93 million in funding to support over 2,800 grants to outstanding cancer researchers at all leading institutions in Israel as well as collaborative research partnerships between Israeli and North American investigators. Many of our grantees are responsible for major cancer research breakthroughs and discoveries.

Recipient(s) Institution Grant Type Research Topics Grant Status
Moshe Giladi, MD, PhD Tel Aviv University Research Career Development Award Cancer Metastasis, Gastrointestinal Cancer, Lung Cancer, Metabolism and Cancer, Oncogenesis, Proteomics and Protein Structures Non-active
Yafit Gilboa, PhD Hebrew University of Jerusalem Brause Family Initiative for Quality of Life Grant Cancer-Related Cognitive Decline, Clinical and Translational Research, Quality of Life Non-active
Zvi Granot, PhD Hebrew University of Jerusalem Research Career Development Award Cancer Metastasis, Immunology and Immunotherapy Non-active
Zvi Granot, PhD Hebrew University of Jerusalem Project Grant Cancer Metastasis, Immunology and Immunotherapy, Inflammation and Cancer Non-active
Shoshana Greenberger, MD, PhD Chaim Sheba Medical Center Project Grant Lymphangiogenesis, Skin Cancer Non-active
Albert Grinshpun, MD, MSc Hebrew University-Hadassah Medical School ICRF-Conquer Cancer (The ASCO Foundation) Career Development Award Breast Cancer Non-active
Joshua Grolman, PhD Technion, Israel Institute of Technology Research Career Development Award Inflammation and the Immune Response Active
Jacob Hanna, MD, PhD Weizmann Institute of Science Research Professorship Grant Experimental Therapeutics, Stem Cells Active
Erez Hasnis, MD, PhD Rambam Health Care Campus ICRF-Israel Ministry of Science and Technology Gesher Award for Academic Excellence in the Field of Cancer Research Animal Modes of Cancer, Cell Signaling, Clinical and Translational Research, Computational Biology, Human Subjects, Pancreatic Cancer, Proteomics and Protein Structures Non-active
Ehud Herbst, PhD Weizmann Institute of Science Postdoctoral Fellowship BacterioOncology Active